Keyphrases
Solid Tumors
71%
Personalized Oncology
43%
Tumor
41%
Advanced Solid Tumors
39%
Copenhagen
35%
Targeted Therapy
35%
Genetic Profile
33%
Immune Checkpoint Inhibitors
33%
Cell-free DNA (cfDNA)
32%
Metastatic Tumor
29%
T Cells
25%
Overall Survival
25%
Patient Selection
25%
Cancer Types
24%
Antitumor Activity
24%
Circulating Tumor DNA (ctDNA)
24%
Treatment Options
23%
Clinical Trials
23%
Clinical Outcomes
23%
Safety Activity
23%
Erlotinib
22%
Pathogenic Germline Variant
22%
Phase 1 Trial
22%
Upper Gastrointestinal Cancer
22%
BRAF V600E
22%
Bevacizumab
22%
Checkpoint Inhibition
22%
Fibroblast Activation Protein
22%
Targeted Treatment
22%
Oncology
22%
Cancer Patients
21%
Epidermal Growth Factor Receptor
21%
Genetic Modification
21%
Atezolizumab
21%
Personalized Cancer Therapy
21%
Tumor Subtype
20%
Precision Cancer Medicine
20%
Genomic Profiling
19%
Anti-drug Antibodies
19%
Whole Exome Sequencing
19%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
18%
Peripheral Blood
18%
Progression-free Survival
17%
Phase II Trial
17%
RNA Sequencing (RNA-seq)
17%
Actionable Target
17%
Oncology Trials
16%
Objective Response
16%
Obinutuzumab
16%
Clinical Oncology
16%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Neoplasm
94%
Malignant Neoplasm
75%
Biological Marker
40%
Clinical Trial
30%
Pharmacodynamics
28%
Progression Free Survival
27%
Overall Survival
27%
Epidermal Growth Factor Receptor
24%
Pharmacokinetics
23%
Erlotinib
22%
Digestive System Cancer
22%
Bevacizumab
22%
Atezolizumab
21%
Carcinoembryonic Antigen
19%
Drug Antibody
16%
Disease
16%
Antitumor Activity
15%
Urokinase Receptor
15%
Cytokine Release Syndrome
15%
Maximum Tolerated Dose
15%
Obinutuzumab
15%
Melanoma
14%
Immune Checkpoint Inhibitor
14%
Bile Duct Carcinoma
14%
Human Study
14%
Phase II Trials
14%
Immunogenicity
13%
Circulating Tumor DNA
12%
Vasculotropin Receptor 2
12%
Sodium Fluoride
11%
Anticarcinogen
11%
Gemcitabine
11%
Oxaliplatin
11%
Capecitabine
11%
Cibisatamab
11%
Ipilimumab
11%
Talazoparib
11%
Nivolumab
11%
Distress Syndrome
11%
Encorafenib
11%
Transitional Cell Carcinoma
11%
Seprase
11%
Head and Neck Cancer
11%
Glioma
11%
Mercaptopurine
11%
Tioguanine
11%
Cergutuzumab Amunaleukin
11%
CD8 Antigen
11%
Metastatic Colorectal Cancer
11%
Medicine and Dentistry
Neoplasm
72%
Malignant Neoplasm
69%
Oncology
46%
Solid Malignant Neoplasm
36%
Clinical Trial
31%
Biological Marker
30%
Targeted Therapy
25%
Medicine
23%
Cell-Free DNA
22%
Metastatic Carcinoma
22%
Disease
19%
Somatics
18%
Biopsy
17%
Immune Checkpoint Inhibitor
16%
RNA Sequence
16%
Immunotherapy
15%
Diagnosis
15%
Tumor Biopsy
15%
Cancer Types
15%
Clinical Oncology
15%
Cancer Therapy
15%
Patient Selection
13%
Transitional Cell Carcinoma
12%
Phase I Trials
12%
Molecularly Targeted Therapy
11%
Gene Expression
11%
Adenocarcinoma
11%
Poly ADP Ribose Polymerase
11%
BRCA1
11%
Ipilimumab
11%
Overall Survival
11%
Molecular Profiling
11%
Hepatocellular Carcinoma
11%
Extracellular Matrix
11%
DNA Damage Response
11%
Colorectal Carcinoma
11%
Immunocompetent Cell
11%
Talazoparib
11%
Circulating Tumor DNA
11%
Nivolumab
11%
Head and Neck Cancer
11%
Experimental Oncology
11%
Sodium Fluoride
11%
Avelumab
11%
Personalized Medicine
11%
Oncologist
11%
Tumor Infiltrating Lymphocyte
11%
Arm
10%
T Cell
10%
Exome Sequencing
10%
